| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Shanghai Yizhong Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥38.65 |
| 52 Week High | CN¥88.44 |
| 52 Week Low | CN¥36.55 |
| Beta | -0.56 |
| 1 Month Change | -19.53% |
| 3 Month Change | -32.64% |
| 1 Year Change | -55.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 18.02% |
Recent News & Updates
Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance
Apr 15
Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely
Mar 29Shareholder Returns
| 688091 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -1.1% | -0.4% |
| 1Y | -55.2% | -15.9% | -16.2% |
Return vs Industry: 688091 underperformed the CN Pharmaceuticals industry which returned -16% over the past year.
Return vs Market: 688091 underperformed the CN Market which returned -17.6% over the past year.
Price Volatility
| 688091 volatility | |
|---|---|
| 688091 Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688091's share price has been volatile over the past 3 months.
Volatility Over Time: 688091's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 304 | Jingsong Zhou | www.yizhongpharma.com |
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. The company develops paclitaxel polymer micelle for treatment of small cell lung cancer. Shanghai Yizhong Pharmaceutical Co., Ltd.
Shanghai Yizhong Pharmaceutical Co., Ltd. Fundamentals Summary
| 688091 fundamental statistics | |
|---|---|
| Market cap | CN¥6.12b |
| Earnings (TTM) | CN¥161.55m |
| Revenue (TTM) | CN¥360.25m |
37.9x
P/E Ratio17.0x
P/S RatioIs 688091 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688091 income statement (TTM) | |
|---|---|
| Revenue | CN¥360.25m |
| Cost of Revenue | CN¥23.62m |
| Gross Profit | CN¥336.63m |
| Other Expenses | CN¥175.08m |
| Earnings | CN¥161.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 1.02 |
| Gross Margin | 93.44% |
| Net Profit Margin | 44.84% |
| Debt/Equity Ratio | 3.0% |
How did 688091 perform over the long term?
See historical performance and comparison